ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Oral Sorafenib Trial Published in The Lancet; Tablets Extend PFS in Metastatic Disease

April 25, 2014

Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival

August 31, 2012

Margaret Kripke Comes Out of Retirement To Become Chief Scientific Officer at CPRIT

December 14, 2012

Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent

January 8, 1982

OMB Cut $150 Million From NCI Request

March 22, 1974

McKay Retires As Fox Chase Executive, Is Succeeded By Donald Leedy As VP.

June 2, 2000